HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $9 price target.
May 02, 2024 | 5:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics maintains a Buy rating and a $9 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $9 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards G1 Therapeutics. This endorsement reaffirms the firm's confidence in G1 Therapeutics' potential, likely encouraging both current and potential investors about the stock's future performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100